Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.
News|Articles|April 29, 2025
Interview Intersection: Expert Interviews From April 2025
Author(s)Emma Andrus, Editor
Dermatology Times is recapping our exclusive expert interviews from the month of April.
Advertisement
Advertisement
Melinda Gooderham, MD, discussed delgocitinib cream’s safety and systemic exposure for chronic hand eczema at the 2025 AAD Annual Meeting. She confirmed minimal systemic absorption, even with maximal use, supporting the product's safety profile. Gooderham emphasized the importance of global regulatory approvals, additional safety data, and future comparative studies to guide prescribing decisions. She also highlighted the potential for off-label use for other eczema types and the need for real-world data on delgocitinib's long-term effectiveness.
Related to this article
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.
Advertisement
Advertisement